The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.

There is provided a test strip assembly for detecting the possible presence of at least one analyte in a sample, a device for detecting the possible presence of at least one analyte in a sample comprising the test strip assembly and methods of detecting the possible presence of at least one analyte in a sample using the device.

Disclosed is a process for in vitro detection of an infection by a dengue virus in an individual, including the following steps: contacting a blood sample from the individual with a ligand specific to the NS1 protein of said dengue virus, to capture NS1 protein if it is present in the blood sample, said ligand being immobilized on a solid support; detecting the presence of NS1 protein via a mass spectrometry reading; and if NS1 protein is detected, concluding that the individual has been infected by dengue virus.

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein epitope from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.

The present invention relates to nucleic acids. In particular, it relates to aptamers capable of binding to a flavivirus structural protein or a flavivirus non-structural protein, useful as therapeutics for preventing, treating and/or diagnosing a flavivirus infection in a patient.

A biosensor comprises first and second molecular components and is capable of displaying protease activity in response to a binding event mediated by first and second binding partners of the biosensor. The first and second binding partners may bind each other directly or may both bind a target molecule. At least the first molecular component comprises an autoinhibited protease, whereby the binding event switches the protease frora an autoinhibited inactive state to a protease active state. The second molecular component may activate the protease of the first molecular component by binding a cross-binder which releases the autoinhibitor or by cleaving a linker which releases the autoinhibitor. The first and second molecular components may both have autoinhibited proteases which reciprocally activate each other.

An apparatus for particle size and a distribution of a population of particle measurements, comprising: a non-monochromatic light source that emits a plurality of a non-monochromatic rays, a medium that includes a particle, wherein the medium is a liquid phase and the particle is suspended within the medium to form a particle-suspension, a droplet of the particle-suspension wherein the droplet is provided with a curved surface, and a detector that is provided with a light providing element.

Certain embodiments of the invention include methods and compositions for evaluating flaviviruses, such as Zika virus, for the purpose of identifying, typing, and/or categorizing/speciation of virus in samples using nucleic acid sequencing.